Asset Details
Do you wish to reserve the book?
Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment
Do you wish to request the book?
Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment
2016
Overview
The current study aims to investigate the neurodevelopment of premature infants after intravitreal injections of bevacizumab (IVB) for the treatment of retinopathy of prematurity (ROP) up to the age of 2 years.
The study design was retrospective observational case series conducted at an institutional referral center. Infants with type 1 ROP were classified into 3 groups: laser only, IVB only, and a combination of IVB and laser treatment. Main Outcome Measures were neurodevelopmental outcomes of the patients after treatment were assessed by Bayley Scales for Infant Development.
Sixty-one patients who finished the neurodevelopmental survey were included. No detrimental effects on neurodevelopment were found in IVB group compared with the patients who received laser treatment only. The patients in the IVB + laser group had a higher incidence of significant mental (p = 0.028) and psychomotor (p = 0.002) impairment at 24 months than the patients in the laser group. The odds ratio of having severe psychomotor defects in the IVB + laser group was 5.3 compared with the laser group (p = 0.041). The causal source for the differences that were detected remained unknown due to lack of randomization in the study and accompanying bias in patient selection.
Two years after laser and/or intravitreal injections of bevacizumab for infants with retinopathy of prematurity, no difference on neurodevelopment for those who received only bevacizumab versus only laser treatment were found. Those infants who required rescue therapy with laser or bevacizumab injection after initial, unsuccessful treatment showed some detrimental, neurodevelopmental effects.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
Angiogenesis Inhibitors - administration & dosage
/ Angiogenesis Inhibitors - adverse effects
/ Angiogenesis Inhibitors - therapeutic use
/ Bevacizumab - administration & dosage
/ Bevacizumab - adverse effects
/ Bevacizumab - therapeutic use
/ Child Development - drug effects
/ Complications and side effects
/ Humans
/ Infant
/ Infant, Extremely Low Birth Weight
/ Infants
/ Intellectual Disability - etiology
/ Laser Therapy - adverse effects
/ Lasers
/ Medicine
/ Medicine and Health Sciences
/ Patients
/ Psychomotor Disorders - etiology
/ Retina
/ Retinopathy of Prematurity - drug therapy
